Cue Biopharma (NASDAQ:CUE) Releases Earnings Results, Beats Estimates By $0.02 EPS

Cue Biopharma (NASDAQ:CUE) announced its quarterly earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02, MarketWatch Earnings reports. Cue Biopharma had a negative return on equity of 63.69% and a negative net margin of 1,142.70%.

Shares of CUE opened at $12.70 on Friday. The business has a 50-day simple moving average of $13.53 and a two-hundred day simple moving average of $19.96. The stock has a market cap of $384.53 million, a price-to-earnings ratio of -8.09 and a beta of 1.95. Cue Biopharma has a 52 week low of $9.11 and a 52 week high of $31.69.

In related news, Director Cameron Gray purchased 5,000 shares of Cue Biopharma stock in a transaction on Tuesday, September 29th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the director now directly owns 672,500 shares in the company, valued at approximately $10,087,500. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 9.50% of the company’s stock.

A number of analysts recently commented on CUE shares. Oppenheimer reiterated a “buy” rating and set a $32.00 price objective on shares of Cue Biopharma in a research report on Tuesday, September 1st. BidaskClub cut Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $31.00.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Earnings History for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with's FREE daily email newsletter.